Petadeferitrin
Pharmacosmos is developing Petadeferitrin, a novel iron chelator, as a new treatment for patients with transfusional iron overload.
Pharmaceuticals
In recent years, Pharmacosmos has conducted more than 25 clinical trials across a range of disease areas affected by iron deficiency anaemia, including chronic kidney disease, inflammatory bowel disease, cardiac surgery, and a number of other populations.
As part of the continued life-cycle activities for Monofer/Monoferric (ferric derisomaltose), Pharmacosmos is currently conducting a pediatric trial in app. 200 patients with iron deficiency anaemia. For more details, please refer to: ClinicalTrials.gov (ID NCT05179226).
As part of the petadeferitrin development program, Pharmacosmos is currently conducting a phase II trial in patients with transfusion-dependent thalassemia and iron overload. For more details, please refer to: ClinicalTrials.gov (ID NCT05693909).
Petadeferitrin is investigational and have not been approved for commercial use anywhere in the world. Safety and efficacy have not been established.
PHARMACOSMOS IS …
A global pioneer in carbohydrate chemistry and a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia.
